Mastering LNP complexity: manufacturing, characterization, and targeting

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Mastering LNP complexity: manufacturing, characterization, and targeting

Dive into the complexities of LNP development with a focus on purification, analytical advances, and targeted delivery. Hear from experts at NeoVac, NanoCell, and Sartorius BIA Separations as they share practical solutions for overcoming CMC hurdles and enhancing therapeutic efficacy.

Attend this session to learn more about:

Size and structure characterization of LNPs for quality evaluation and understanding mechanism of action
Enabling precise separation of complex, multi-cargo formulations
A novel CAR-T approach using targeted LNP formulations to generate functional CAR-T cells in vivo for a simplified approach to advanced oncological therapies
Advanced analytical techniques for insights into particle heterogeneity and nucleic acid content
Transitioning LNPs from concept to clinic

Timings:

Session Introduction, Roisin McGuigan (00:00-01:20)
Supramolecular Organization's Role in mRNA LNP Quality, Impact of Structure on mRNA LNP Quality, Heinrich Haas (01:20-28:00)
CMC and Manufacturing Challenges in LNP-Based Biopharmaceuticals, Overcoming Manufacturing Challenges in LNP Biopharmaceuticals, Tristan Kovacic (28:00-51:00)
Enhanced Purification for Complex LNP Formulations, Improved Purification for Complex LNP Formulations, Mojca Tajnik Sbaizero (51:00-01:20:00)
Innovative tLNP Platform for In Vivo CAR-T Engineering, New DNA-Based Gene Therapy for CAR T Cells, Jacek Lubelski (01:20:00-01:51:00)

Tristan Kovačič

Scientist, Process Analytics Development Department at Sartorius BIA Separations

Tristan Kovacic is a Scientist in the Process Analytics Development Department at Sartorius BIA Separations and a PhD student in Computational Chemistry at the University of Maribor. He has experience in the pharmaceutical and biotech industries, focusing on process development and analytics for non-viral drug delivery systems and active pharmaceutical ingredients.

Mojca Tajnik Sbaizero

Head of Product Application Area at Sartorius BIA Separations

Mojca Tajnik Sbaizero, PhD, leads the Virus and Nanoparticle Innovation Group at Sartorius BIA Separations. Her prior academic work focused on pre-mRNA processing and therapeutic strategies for genetic alternative splicing diseases. At Sartorius BIA Separations she focuses on downstream processing of viral vectors and vaccines, with recent projects emphasizing LNP process development.

Jacek Lubelski

Chief Technology Officer at NanoCell

Jacek Lubelski, PhD, is a biopharmaceutical leader specializing in gene and cell therapy and viral vector production, with over a decade of experience advancing rAAV therapeutics. Previously, as VP of Pharmaceutical Development at UniQure NV, he helped obtain market authorization for Glybera, the first approved gene therapy for LPL deficiency. Now, as CTO at NanoCell Therapeutics, he oversees R&D activities.

Heinrich Haas

Chief Technology Officer at NeoVac

Heinrich Haas, PhD, has worked both in academia, where he researched lipid membranes and organized bio-molecular systems and the pharmaceutical industry (Munich Biotech, Medigene, BioNTech, where he developed nanoparticle products to clinical stage. His focus is on advanced approaches for nanoparticle development and control.

You have registered for this webinar